The content discusses the challenges of treating advanced cutaneous squamous cell carcinoma (cSCC) in organ transplant recipients. The use of immune checkpoint inhibitors is limited due to the potential risk of organ rejection. Organ transplant recipients have a higher risk of developing cSCC, and treatment options are limited due to the impact of immunosuppressant medications. The article also covers the need for preventive strategies and the importance of coordinating care between dermatologists and transplant specialists. Studies on acitretin and nicotinamide as potential preventive therapies are discussed, as well as the challenges and limitations of using immune checkpoint inhibitors. The article also highlights the need for additional research in this area.
Source link
Tools on the Horizon for Managing Posttransplant cSCC Risk
